Novavax
Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland. In 2018, Novavax received a US$89 million research grant from the Bill and Melinda Gates Foundation for development of vaccines for maternal immunization. The company’s first phase III trial, the 12,000 adult Resolve trial, for its respiratory syncytial virus vaccine, failed in September. This triggered an eighty-five percent...